Halozyme expands ENHANZE collaboration with argenx to cover two additional exclusive targets
HALO•Halozyme expanded its global collaboration with argenx to develop subcutaneous formulations for two additional exclusive targets using ENHANZE, increasing argenx’s exclusive access from six targets to eight. Halozyme remains eligible for milestone payments and royalties on net sales of products using ENHANZE.
1. Expanded collaboration
Halozyme expanded its global collaboration with argenx to develop subcutaneous formulations for two additional exclusive targets using ENHANZE. The deal raises argenx’s exclusive access to ENHANZE targets from six to eight. Halozyme remains eligible for milestone payments and royalties on net sales of products using ENHANZE.
